These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22916799)

  • 1. Cardiovascular effects of melatonin receptor agonists.
    Paulis L; Simko F; Laudon M
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1661-78. PubMed ID: 22916799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-hypertensive action of melatoninergic compounds].
    Inoue Y
    Nihon Rinsho; 2014 Aug; 72(8):1386-94. PubMed ID: 25167740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melatonin in cardiovascular disease.
    Dominguez-Rodriguez A
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1593-6. PubMed ID: 22916801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melatonin receptors as therapeutic targets in the suprachiasmatic nucleus.
    Pévet P
    Expert Opin Ther Targets; 2016 Oct; 20(10):1209-18. PubMed ID: 27082492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in melatonin receptor ligands.
    Zlotos DP
    Arch Pharm (Weinheim); 2005 Jun; 338(5-6):229-47. PubMed ID: 15952241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists.
    Mor M; Rivara S; Pala D; Bedini A; Spadoni G; Tarzia G
    Expert Opin Ther Pat; 2010 Aug; 20(8):1059-77. PubMed ID: 20533893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docking studies for melatonin receptors.
    Alkozi HA; Sánchez Montero JM; Doadrio AL; Pintor J
    Expert Opin Drug Discov; 2018 Mar; 13(3):241-248. PubMed ID: 29271261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.
    Zlotos DP; Jockers R; Cecon E; Rivara S; Witt-Enderby PA
    J Med Chem; 2014 Apr; 57(8):3161-85. PubMed ID: 24228714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.
    Liu J; Clough SJ; Hutchinson AJ; Adamah-Biassi EB; Popovska-Gorevski M; Dubocovich ML
    Annu Rev Pharmacol Toxicol; 2016; 56():361-83. PubMed ID: 26514204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian rhythms, melatonin and depression.
    Quera Salva MA; Hartley S; Barbot F; Alvarez JC; Lofaso F; Guilleminault C
    Curr Pharm Des; 2011; 17(15):1459-70. PubMed ID: 21476953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists.
    Jeanty M; Suzenet F; Delagrange P; Nosjean O; Boutin JA; Caignard DH; Guillaumet G
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2316-9. PubMed ID: 21420861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular cloning and pharmacological characterization of monkey MT1 and MT2 melatonin receptors showing high affinity for the agonist ramelteon.
    Nishiyama K; Shintani Y; Hirai K; Yoshikubo S
    J Pharmacol Exp Ther; 2009 Sep; 330(3):855-63. PubMed ID: 19556449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endogenous melatonin (MT) signal facilitates reentrainment of the circadian system to light-induced phase advances by acting upon MT2 receptors.
    Pfeffer M; Rauch A; Korf HW; von Gall C
    Chronobiol Int; 2012 May; 29(4):415-29. PubMed ID: 22489607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute sleep-promoting action of the melatonin agonist, ramelteon, in the rat.
    Fisher SP; Davidson K; Kulla A; Sugden D
    J Pineal Res; 2008 Sep; 45(2):125-32. PubMed ID: 18298466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
    Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
    Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms.
    Stein RM; Kang HJ; McCorvy JD; Glatfelter GC; Jones AJ; Che T; Slocum S; Huang XP; Savych O; Moroz YS; Stauch B; Johansson LC; Cherezov V; Kenakin T; Irwin JJ; Shoichet BK; Roth BL; Dubocovich ML
    Nature; 2020 Mar; 579(7800):609-614. PubMed ID: 32040955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune hepatitis in association with ramelteon.
    Fourman LT; Robert Meyer B
    J Clin Gastroenterol; 2013 Aug; 47(7):651-4. PubMed ID: 23632362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
    Leger D; Quera-Salva MA; Vecchierini MF; Ogrizek P; Perry CA; Dressman MA
    Expert Opin Drug Saf; 2015; 14(11):1673-85. PubMed ID: 26393492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT₂-selective agonists.
    Koike T; Hoashi Y; Takai T; Nakayama M; Yukuhiro N; Ishikawa T; Hirai K; Uchikawa O
    J Med Chem; 2011 May; 54(9):3436-44. PubMed ID: 21473625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A novel therapeutic drug: ramelteon].
    Miyamoto M
    Nihon Rinsho; 2009 Aug; 67(8):1595-600. PubMed ID: 19768947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.